Abcuro

Executive Summary

Abcuro is a clinical-stage biotechnology company developing precision therapies for autoimmune diseases and cancer by targeting highly cytotoxic T cells. Founded in 2016 and based in Newton, MA, the company's lead candidate, ulviprubart, is a monoclonal antibody designed to selectively deplete pathogenic KLRG1+ cytotoxic T cells. This approach aims to address the root cause of several autoimmune disorders where these cells drive tissue damage. Abcuro's platform has the potential to offer disease-modifying treatments with improved safety and efficacy compared to broad immunosuppression. Abcuro has advanced ulviprubart into a Phase 2/3 trial for inclusion body myositis (IBM) and a Phase 2 trial for myasthenia gravis (MG). The IBM program is one of the few late-stage studies for this rare, progressive muscle disease, with no approved therapies. Positive data could establish a new standard of care and address a significant unmet need. The MG program targets a large autoimmune population where existing treatments often have limited efficacy. Abcuro's differentiated mechanism and early clinical signals position it as a promising player in the autoimmune space. With multiple value-inflecting milestones on the horizon, the company represents a compelling opportunity in targeted immunotherapy.

Upcoming Catalysts (preview)

• H2 2026Phase 2/3 interim data for ulviprubart in inclusion body myositis60% success
• Q1 2027Phase 2 top-line results for ulviprubart in myasthenia gravis50% success
• Q3 2026Series C financing or strategic partnership70% success